Abzena Completes Cell-Line for BiosimilarBy
Abzena, a contract manufacturer of biologics and antibody drug conjugates, has begun the installation of a new 500-liter single-use bioreactor as part of a series of investments in its process development and manufacturing operations in San Diego, California.
Abzena currently has drug-development capabilities through discovery, optimization, cell-line development, process development, and manufacturing including in single-use wave bags from 10 liters to 500 liters.
The new bioreactor is scheduled to be on line in January 2018 for preclinical and Phase I and Phase II clinical-trial product production. The installation also includes four 25-liter single-use, wave-mixed bioreactors proven for different cell lines, including Chinese hamster ovary (CHO), NS0, and SF9 for seeding the 500-liter bioreactor, and a FlexAct system from Sartorius Stedim Biotech, a supplier for the biopharmaceutical industry, for a disposable solution for cell harvesting with associated pallet tanks.